Bedminster-based NPS Pharmaceuticals Inc. announced Tuesday the appointment and promotion of two key executives to support the company’s vision in being a global provider of orphan drugs.According to the announcement, Paul Firuta has joined NPS as president, U.S. commercial operations. He was most recently vice president and general manager at Americas for ViroPharma Inc. While at ViroPharma, Firuta led the U.S. launch of Cinryze, an orphan biologic product to help patients with hereditary angioedema. The product generated $97 million in sales its first year, making it one of the most successful orphan drug launches in the U.S.
Eric Pauwels has been promoted to the new position of president, NPS Pharma International and will be responsible for international commercial operations. He joined NPS in 2011 and has created a commercial team and directed the successful U.S. launch of Gattex, an injection for adult short bowel syndrome, the announcement said.
ALSO ON NJBIZ:
SLIDESHOW: NJBIZ Health Care Power 50
In light of Tesla ban, lawmakers introduce bill allowing direct sales for electric cars